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SUMMARY
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic is continuing to disrupt per-
sonal lives, global healthcare systems, and economies. Hence, there is an urgent need for a vaccine that pre-
vents viral infection, transmission, and disease. Here, we present a two-component protein-based nanopar-
ticle vaccine that displays multiple copies of the SARS-CoV-2 spike protein. Immunization studies show that
this vaccine induces potent neutralizing antibody responses in mice, rabbits, and cynomolgus macaques.
The vaccine-induced immunity protects macaques against a high-dose challenge, resulting in strongly
reduced viral infection and replication in the upper and lower airways. These nanoparticles are a promising
vaccine candidate to curtail the SARS-CoV-2 pandemic.
INTRODUCTION
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
has rapidly spread across the globe and infected more than 100
million individuals since late 2019 (https://covid19.who.int/).
SARS-CoV-2 causes coronavirus disease 2019 (COVID-19),
whichmanifests itself as amild respiratory illness inmost infected
individuals but can lead to acute respiratory distress syndrome
and death in a significant percentage of cases. As of February
1st, 2021, COVID-19 has caused over 2 million casualties and
continues to place a significant burden on healthcare systems
and economies worldwide. Hence, the development of a safe
and effective vaccine that can prevent SARS-CoV-2 infection
and transmission has rapidly become a top priority.
Recent studies suggest thatSARS-CoV-2-specific neutralizing
antibody (NAb) titers are an important immune correlate of pro-
tection (Addetia et al., 2020; Yu et al., 2020). This is supported
by several passive immunization studies showing that adminis-
tration of potent neutralizing SARS-CoV-2-specific monoclonal
antibodies (mAbs) can significantly reduce lung viral loads (Cao
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et al., 2020; Rogers et al., 2020). Thus, a successful vaccine will
likely need to induce a potent NAb response. The main target
for NAbs on SARS-CoV-2 is the spike (S) protein. This homotri-
meric glycoprotein is anchored in the viral membrane and con-
sists of the S1 domain, which contains the receptor-binding
domain (RBD) for the host cell receptor angiotensin-converting
enzyme 2 (ACE2), and the S2 domain, which contains the fusion
peptide. Upon binding to ACE2, the prefusion S protein un-
dergoes several structural changes that induce a shift to a post-
fusion state that enables merging of the viral envelope and host
cell membrane (Shang et al., 2020). As most NAb epitopes are
presented on the prefusion conformation, vaccine candidates
should include the prefusion S protein, which, as for other class
I viral fusion proteins (Krarup et al., 2015; Sanders et al., 2002),
can be stabilized by appropriately positioned proline substitu-
tions (Pallesenet al., 2017;Walls et al., 2020a;Wrappet al., 2020).
More than200candidatevaccinesarecurrentlyunderpreclinical
or clinical evaluation, and several have been licensed (https://
www.who.int/publications/m/item/draft-landscape-of-covid-19-
candidate-vaccines). Recombinant subunit vaccines provide a
welcome alternative to the inactivated, viral-vector- and RNA-
based vaccines that are currently in phase 3 clinical trials or in
use, as they have a track record of safety and efficacy. In addition,
recombinantly expressed S proteins represent an efficient antigen
to induce potent NAb responses, as recently reported in non-hu-
man primate studies (Guebre-Xabier et al., 2020; Liang et al.,
2020; Tian et al., 2021).
A well-established strategy to generate strong humoral im-
mune responses against soluble antigens is multivalent antigen
display (Bachmann and Jennings, 2010; Moyer et al., 2016).
Nanoparticles presenting a high density of antigen on a repeti-
tive array facilitate numerous immunological processes such
as B cell activation, lymph node trafficking, and retention on
follicular dendritic cells (Kelly et al., 2019; Tokatlian et al.,
2019). Among the several nanoparticle designs that are
currently being employed to present viral glycoproteins, self-
assembling protein nanoparticle systems represent promising
platforms, as they allow for efficient and scalable nanoparticle
assembly (López-Sagaseta et al., 2015). Homomeric protein
complexes such as the 24-subunit ferritin and 60-subunit mi3
nanoparticles self-assemble intracellularly and have been
used to display immunogens such as influenza hemagglutinin
(HA), HIV-1 Env, malaria cysteine-rich protective antigen (Cy-
RPA), and also SARS-CoV-2 S protein and RBD (Bruun et al.,
2018; He et al., 2020; Kanekiyo et al., 2013; Ma et al., 2020; Po-
well et al., 2021; Sliepen et al., 2015; Walls et al., 2020b).
Recently, two-component 120-subunit icosahedral nanopar-
ticles, such as the I53-50 and dn5 designs, have been devel-
oped that self-assemble in vitro, allowing for controlled nano-
particle formation. We and others have been using these
nanoparticles to multivalently present trimeric type 1 viral fusion
proteins of HIV-1, respiratory syncytial virus (RSV), and influenza
(Boyoglu-Barnum et al., 2020; Brouwer et al., 2019; Marcandalli
et al., 2019). Presentation of these immunogens on two-compo-
nent protein nanoparticles significantly improved NAb titers,
which supports pursuing this platform for the generation of
nanoparticle immunogens displaying prefusion SARS-CoV-2 S
proteins.
Here, we describe the generation and characterization of two-
component protein nanoparticles displaying stabilized prefusion
SARS-CoV-2 S proteins. Immunization studies in mice, rabbits,
and macaques demonstrated that these nanoparticles induce
robust humoral responses. Vaccinated macaques challenged
with a high dose of SARS-CoV-2 virus had strongly reduced viral
loads in both the upper and lower respiratory tracts and devel-
oped fewer lung lesions when compared to unvaccinated
animals.
RESULTS
SARS-CoV-2 S proteins can be displayed on two-
component I53-50 nanoparticles
The computationally designed I53-50 nanoparticle (I53-50NP)
constitutes 20 trimeric (I53-50A or variants thereof) and 12 pen-
tameric (I53-50B.4PT1) subunits that self-assemble to form
monodisperse icosahedral particles with a diameter of 30 nm
(Bale et al., 2016). To generate I53-50NPs presenting SARS-
CoV-2 S proteins, we genetically fused the C terminus of the pre-
viously described stabilized prefusion S protein to the N terminus
of the I53-50A variant, I53-50A.1NT1, using a glycine-serine
linker (Figure 1A; Brouwer et al., 2020). The fusion protein was
purified from transfected human embryonic kidney (HEK) 293F
cell supernatant using nickel-nitrilotriacetic acid (Ni-NTA) purifi-
cation followed by size exclusion chromatography (SEC). Collec-
tion of the appropriate SEC fractions yielded 2 mg/L trimeric
SARS-CoV-2 S-I53-50A.1NT1 fusion protein (Figure 1B). To
initiate assembly of nanoparticles presenting SARS-CoV-2 S
proteins (SARS-CoV-2 S-I53-50NPs), the pooled trimer fractions
were incubated overnight at 4C with I53-50B.4PT1 in an equi-
molar ratio. The nanoparticle preparation was further purified us-
ing an additional SEC step to remove unassembled compo-
nents. Negative-stain electron microscopy (nsEM) of the
pooled higher-molecular-weight fractions revealed a consider-
able portion of monodisperse and well-ordered icosahedral
nanoparticles (Figure 1C). Biolayer interferometry (BLI)-based
binding experiments with a panel of SARS-CoV-2 S-protein-spe-
cific monoclonal NAbs, previously isolated from recovered
COVID-19 patients (Brouwer et al., 2020), showed strong binding
of RBD-specific COVA1-18, COVA2-02, COVA2-15, and
COVA2-39 and N-terminal domain (NTD)-specific COVA1-22 to
trimeric SARS-CoV-2 S-I53-50A.1NT1 and SARS-CoV-2 S-I53-
50NP (Figure 1D). This suggests that presentation of SARS-
CoV-2 S protein on I53-50NPs did not compromise the structure
of these S protein epitopes. Altogether, SEC, nsEM, and BLI
confirmed the successful generation of nanoparticles presenting
multiple copies of the SARS-CoV-2 S protein.
As approximately one-third of the mass of the SARS-CoV-2 S
protein consists of N-linked glycans, we sought to identify the
site-specific glycosylation of S protein presented on I53-50NPs
using liquid chromatography-mass spectrometry (LC-MS). All
sites presented high levels of occupancy, with only N1074 dis-
playing 15% of sites lacking an N-linked glycan (Figure S1A).
The compositions of glycans present at the 19 N-linked glycan
sites on the S protein were determined and revealed a diverse
range of structures (Figure S1B). Underprocessed oligoman-
nose-type glycans were observed at sites N61, N234, N717,
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and N801 and to a lesser extent at N1098. The average oligo-
mannose-type glycan content across all sites was 11%. Pro-
cessed complex-type glycans were observed at all sites and
were highly fucosylated (73%) but mostly lacked sialylation
(8%) (Figures S1A and S1B). The glycoforms present on
SARS-CoV-2 S-I53-50NPs are more processed compared to
other recombinant S protein immunogens (Watanabe et al.,
2020) but are reminiscent of the composition on S proteins pre-
sented on virions (Yao et al., 2020).
SARS-CoV-2 S-I53-50NPs enhance activation of SARS-
CoV-2 S-protein-specific B cells in vitro
Multivalent display of antigens can enhance cognate B cell
activation over soluble antigen (Antanasijevic et al., 2020;
Brouwer et al., 2019; Veneziano et al., 2020). To assess if
the same would apply for SARS-CoV-2 S-I53-50NPs, we
generated B cells that expressed B cell receptors (BCRs) for
previously described RBD-targeting monoclonal NAbs and
measured their activation by monitoring Ca2+ influx in vitro
(Brouwer et al., 2020). Soluble trimers only weakly activated
COVA1-18-expressing B cells at the highest concentration
used (5 mg/mL SARS-CoV-2 S-I53-50A.1NT1), while an
equimolar amount of SARS-CoV-2 S presented on I53-50NPs
efficiently activated the same B cells (Figure 2). COVA2-15-
expressing B cells were activated by soluble SARS-CoV-2
S-I53-50A.1NT1 trimers but markedly more efficiently so by
SARS-CoV-2 S-I53-50NP. The more efficient activation
of COVA2-15-expressing B cells compared to those ex-
pressing COVA1-18 may be explained by the fact that
COVA2-15 can interact with the RBD in both the up and
down state, which may result in higher-avidity interactions
Figure 1. Biophysical and antigenic charac-
terization of SARS-CoV-2 S-I53-50NPs
(A) Schematic representation of 20 copies of
SARS-CoV-2 S-I53-50A.1NT1 (SARS-CoV-2 S in
light blue, glycans in dark blue, and I53-50A.1NT1
in white) and 12 copies of I53-50B.4PT1 assem-
bling into SARS-CoV-2 S-I53-50NP.
(B) Size exclusion chromatograms of SARS-CoV-2
S-I53-50A.1NT1 (magenta) and SARS-CoV-2 S-
I53-50NP (green) run over a Superose 6 increase
10/300 GL column. The yellow columns specify the
SEC fractions that were collected, pooled, and
used. Blue native gel of pooled SARS-CoV-2 S-
I53-50A.1NT1 SEC fractions.
(C) Negative-stain electron microscopy (nsEM)
analysis of assembled SARS-CoV-2 S-I53-50NPs.
The white bar represents 200 nm.
(D) BLI sensorgrams showing the binding of mul-
tiple SARS-CoV-2 NAbs to SARS-CoV-2 S-I53-
50A.1NT1 (magenta) and SARS-CoV-2 S-I53-
50NP (green).
See also Figure S1.
(Brouwer et al., 2020). In control experi-
ments, I53-50NPs displaying soluble
HIV-1 envelope glycoproteins (BG505
SOSIP) did not activate any of the B
cell lines. We conclude that SARS-
CoV-2 S-I53-50NPs improve the activation of SARS-CoV-2-
specific B cells compared to soluble trimers.
SARS-CoV-2 S-I53-50NP vaccination induces robust
NAb responses in small-animal models
We assessed the immunogenicity of SARS-CoV-2 S-I53-50NPs
in two small-animal models. Eight BALB/c mice were immu-
nized with 10 mg SARS-CoV-2 S presented on I53-50NPs, adju-
vanted in polyinosinic-polycytidylic acid (poly(I:C)). In addition,
five New Zealand white rabbits were immunized with 30 mg
SARS-CoV-2 S presented on I53-50NPs, adjuvanted in squa-
lene emulsion. Mice and rabbits received three subcutaneous
and intramuscular immunizations, respectively, at weeks 0, 4,
and 12 (Figure 3A). The adjuvants were chosen based on our
previous positive experiences with them in the respective ani-
mal models.
Two weeks after the first immunization, mice and rabbits
induceddetectableSARS-CoV-2S-protein-specific immunoglob-
ulinG (IgG) titers, as determinedby an enzyme-linked immunosor-
bent assay (ELISA), with a median endpoint binding titer of 2,920
and 5,105 respectively. In mice, median endpoint titers were
further boosted after the second immunization to 57,943 at week
6 and slightly decreased after the third immunization to 47,643 at
week 14 (Figure 3B). In rabbits, median endpoint titers were
boosted to 544,503 at week 6 and 594,292 at week 14 (Figure 3C).
Neutralization of SARS-CoV-2 pseudovirus was already detect-
able in the majority of mice and rabbit sera 2 weeks after the first
immunization. NAb titers, which are represented by the inhibitory
dilutions at which 50% neutralization is attained (ID50 values),
increased to a median of 16,792 at week 6 and 49,039 at week
14 in mice (Figure 3D; Table S1). In rabbits, NAb titers were
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boosted toamedian ID50of68,298and135,128atweeks6and14,
respectively (Figure 3E; Table S1). Neutralization titers of authentic
SARS-CoV-2 virus at week 14 reached amedian ID50 of 4,065 and
15,110 inmice and rabbits, respectively (Figures 3D and 3E; Table
S1). Collectively, we showed that SARS-CoV-2S-I53-50NPswere
able to induce robust binding andNAb responses inbothmiceand
rabbits after two and three immunizations.
SARS-CoV-2 S-I53-50NP vaccination induces potent
humoral responses in cynomolgus macaques
The high binding and neutralization titers in mice and rabbits
supported subsequent assessment of the immunogenicity of
SARS-CoV-2 S-I53-50NPs in cynomolgus macaques, an animal
model that is immunologically closer to humans. Six cynomolgus
macaques were immunized with 50 mg SARS-CoV-2 S-I53-
50NPs formulated in monophospholipid A (MPLA) liposomes
by the intramuscular route at weeks 0, 4, and 10 (Fig-
ure 4A). The MPLA liposome adjuvant was chosen because it
is used in several human clinical trials (e.g., NCT03816137,
NCT03961438, and NCT04046978) and is a component of the
widely used AS01 adjuvant, which was safe and effective in
several phase 3 clinical trials (Lal et al., 2018; Agnandji
et al., 2012).
To analyze the frequency of S protein and RBD-specific IgG-
positive B cells in macaques after vaccination, peripheral blood
mononuclear cells at week 12 were gated on the expression of
CD20 and IgG and stained with fluorescently labeled prefusion
SARS-CoV-2 S protein or RBD (Figure 4B). We observed a clear
expansion of SARS-CoV-2 S-protein-specific B cells by vaccina-
tion, which constituted on average 1% of total B cells (Fig-
ure 4C). Within the population of IgG-positive SARS-CoV-2 S-
protein-specific B cells, on average, 30% bound to the RBD
(Figure 4C). Within the CD27+ B cell population (marker for mem-
ory B cells), on average, 0.77%were SARS-CoV-2 S protein spe-
cific, of which, again, 30% were specific for the RBD (Fig-
ure S2). In addition to B cells, SARS-CoV-2 S-protein-specific
T cells were also markedly expanded, as determined by an
enzyme-linked immune absorbent spot assay (ELISpot) (Fig-
ure 4D). Furthermore, we studied circulating T follicular helper
cells (cTfh cells), the circulating counterpart of germinal center
Tfh cells (Heit et al., 2017; Vella et al., 2019). We observed pro-
nounced expansion of S-protein-specific cTfh cells (CD69+
CD154+ CXCR5+) within the CD4+ T cell subset, as determined
by the activation-induced marker (AIM) assay (Figures 4E and
S3A–S3C). Within CD4 T cells (CD8+ T cells by inference), a
trend toward higher expansion of cells was observed in the
vaccinated macaques (Figure S3D)
Sera of the immunized macaques exhibited SARS-CoV-2 S-
protein-specific binding IgG responses with median endpoint ti-
ters of 211, 1,601 and 2,190, at weeks 2, 6, and 12, respectively
(Figure 5A). To compare binding titers to SARS-CoV-2 S protein
and RBD between sera from vaccinated macaques and those
from convalescent humans from the COVID-19 Specific Anti-
bodies (COSCA) cohort (sampled 4 weeks after the onset of
symptoms) (Brouwer et al., 2020), a different ELISA protocol
was used. Specifically, binding responses were compared to a
standard curve of species-specific polyclonal IgG so that a semi-
quantitative measure of specific IgG concentrations could be
obtained. Week 6 and 12 sera elicited markedly higher IgG bind-
ing titers to SARS-CoV-2 S protein than serum from convales-
cent humans (Figure 5B). This was also the case for RBD-spe-
cific binding titers (Figure 5C).
Figure 2. In vitro B cell activation by SARS-CoV-2 S-I53-50A.1NT1 and SARS-CoV-2 S-I53-50NPs
B cells expressing the SARS-CoV-2 S-protein-specific NAbs COVA1-18 (top) or COVA2-15 (bottom) as BCRs were incubated with either SARS-CoV-2 S-I53-
50A.1NT1 (magenta), SARS-CoV-2 S-I53-50NP (green), ionomycin (beige), or BG505 I53-50NP (gray) or not stimulated (black). The experiments were performed
with 5, 1, 0.2, or 0.04 mg/mL SARS-CoV-2 S-I53-50A.1NT1, as indicated in the top left corner of each graph, or the equimolar amount of SARS-CoV-2 S or BG505
SOSIP on I53-50NPs. Ionomycin was used at 1 mg/mL as a positive control.
ll
OPEN ACCESS
4 Cell 184, 1–13, March 4, 2021
Please cite this article in press as: Brouwer et al., Two-component spike nanoparticle vaccine protects macaques from SARS-CoV-2 infec-
tion, Cell (2021), https://doi.org/10.1016/j.cell.2021.01.035
Article
Using a custom Luminex-bead-based serological assay, we
analyzed the induction of several Ig isotypes in serum, nasopha-
ryngeal swab, and saliva samples of the vaccinated macaques
over time. S-protein-specific IgG levels in serumshoweda similar
course as observed byELISA (Figures 5DandS4A). Thiswasalso
the case for IgA, albeit with a more rapid onset and waning after
vaccination. As expected, IgM levels peaked after the first immu-
nization and gradually waned thereafter, presumably as a result
of Ig class switching (Figures 5D and S4A). We also observed
an increase in S-specific IgG and IgA levels in nasopharyngeal
swabs and saliva after consecutive immunizations. This was
particularly clear for IgG in nasopharyngeal swabs (Figures 5D
and S4B). The results in saliva samples were more variable (Fig-
ures 5D and S4C). Thus, in addition to a systemic antibody
response, SARS-CoV-2 S-I53-50NPs induced detectable
mucosal IgA and IgG responses, a relevant finding considering
that the respiratory mucosa is the first port of entry for SARS-
CoV-2 (Sungnak et al., 2020). Finally, we analyzed the ability of
SARS-CoV-2 S-protein-specific serum antibodies to bind to im-
mune proteins that play a role in Fc-mediated effector functions.
The levels of FcgRIIa, FcgRIIIa, andC1q binding trackedwith IgG
levels, suggesting that the induced IgGs can perform effector
functions such as antibody-dependent cellular-cytotoxicity,
phagocytosis, and complement activation (Figure S4D).
Figure 3. Immunogenicity of SARS-CoV-2
S-I53-50NPs in mice and rabbits
(A) Study schedule in mice (left) and rabbits (right).
Black triangles indicate the time points of immu-
nization and drops indicate the bleeds.
(B) ELISA endpoint titers for SARS-CoV-2 S-pro-
tein-specific IgG in mice.
(C) ELISA endpoint titers for SARS-CoV-2 S-pro-
tein-specific IgG in rabbits.
(D) SARS-CoV-2 pseudovirus and authentic virus
neutralization titers in mice.
(E) SARS-CoV-2 pseudovirus and authentic virus
neutralization in rabbits.
In (B) and (C), due to limited volumes of sera at
week 1, random pairs of mice sera were pooled.
At week 6, two animals were sacrificed. In (B)–(E),
the median titers are indicated by a bar. Titers
between boosts were compared using the Mann-
Whitney U test (*p < 0.05; **p < 0.01; ***p < 0.001).
Serum neutralization titers in the vacci-
natedmacaqueswere overall robust. Two
weeks after the first immunization, ma-
caques induced pseudovirus neutraliza-
tion with a median ID50 of 475. The
second immunization increased the
neutralization titers to a median ID50 of
8,865, which then declined only modestly
up to the third immunization. NAb titers
were further increased to a median ID50
of 26,361 at week 12 (Figure 5E; Table
S2). At week 6, the neutralization titers
were similar to those in sera from conva-
lescent humans, but neutralization titers
at week 12 were significantly higher in vaccinated macaques
than convalescent humans (median ID50 of 26,361 versus
8,226, p = 0.0012) (Figure 5F). Neutralization of authentic
SARS-CoV-2 was lower than that of pseudovirus but remained
potent (median ID50 of 1,501 and 3,942 at weeks 6 and 12,
respectively) (Figure 5G; Table S2).
SARS-CoV-2 S-I53-50NP vaccination protects
cynomolgus macaques from high-dose SARS-CoV-2
challenge
To assess the protective potential of SARS-CoV-2 S-I53-50NPs,
vaccinated macaques and contemporaneous control macaques
(n = 4) were infected with a total dose of 13 106 plaque-forming
units (PFUs) of a primary SARS-CoV-2 isolate (BetaCoV/France/
IDF/0372/2020; passaged twice in VeroE6 cells) by combined
intranasal (0.25 mL in each nostril) and intratracheal (4.5 mL in
the trachea) routes at week 12, 2 weeks after the final immuniza-
tion. This represents a high-dose challenge in comparison with
other studies, where 10- to 100-fold lower doses were used
(van Doremalen et al., 2020; Feng et al., 2020; Guebre-Xabier
et al., 2020; Mercado et al., 2020; Patel et al., 2020; Yu et al.,
2020). Control animals had high viral load levels in nasopharyn-
geal and tracheal samples (swabs), as assessed by qRT-PCR
for viral RNA, as early as 1 day post-exposure (dpe). In tracheal
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samples, viral loads peaked between 1 and 3 dpe, with a median
value of 6.9 log10 copies/mL. Subsequently, viral loads progres-
sively decreased, and all animals had undetectable viral loads by
14 dpe (Figures 6A and S5). Similar profiles were observed in
nasopharyngeal swabs, although viral loads remained detect-
able in somemacaques at 14 dpe (Figures 6A and S5). Viral loads
were markedly lower in rectal samples but stayed above the limit
of detection during the course of sampling for two out of four
control macaques (Figure S5). Viral subgenomic RNA (sgRNA),
which is believed to reflect viral replication, peaked at 2 dpe in
tracheal and nasopharyngeal swabs (median viral sgRNA load
4.8 and 6.1 log10,respectively) and was still detectable (>2.5
log10 copies/mL of viral sgRNA) at 5 and 6 dpe in the naso-
pharynx for three and two animals, respectively (Figure 6B).
In vaccinated macaques, median peak viral loads were 300-
fold lower in tracheal samples (6.8 log10 versus 4.3 log10; p =
0.0095) and 500-fold lower in nasopharyngeal samples
compared to unvaccinated controls (7.9 log10 versus 5.2 log10;
p = 0.0095). With the exception of MF7, all vaccinated animals
had undetectable loads at 6 dpe in tracheal and nasopharyngeal
Figure 4. SARS-CoV-2 S-protein-specific B and T cell responses induced by SARS-CoV-2 S-I53-50NPs in cynomolgus macaques
(A) Vaccination, challenge, and sampling schedule in cynomolgus macaques. Black triangles indicate the time points of vaccination and drops mark the bleeds.
The symbols identifying individual macaques are used consistently throughout Figures 4, 5, and 6.
(B) Representative gating strategy, depicting the analysis of SARS-CoV-2 S protein and RBD-specific IgG+ B cells, shown for one vaccinated macaque. The
lymphocyte population was selected, and doublets were excluded (not shown). Gating strategy from the left to the right: viable B cells (live/deadCD20+), IgG+ B
cells (IgMIgG+), SARS-CoV-2 S protein (double probe staining), and RBD-specific (single probe staining) IgG+ B cells.
(C) SARS-CoV-2 S-protein-specific B cell frequencies within the IgG+ population in control and vaccinated macaques (left). Percentages of SARS-CoV-2 RBD-
specific B cells within the population of SARS-CoV-2 S-protein-specific IgG+ B cells (right).
(D) Number of interferon-g (IFNg)-secreting cells after ex vivo stimulation with SARS-CoV-2 S protein as analyzed by ELISpot and plotted as spot-forming cells
(SFCs) per 1.0 3 106 peripheral blood mononuclear cells (PBMCs).
(E) Frequency of SARS-CoV-2 S-protein-specific Tfh cells (CD69+CD154+CXCR5+) in the total CD4+ T cell population. PBMCs were stimulated overnight with
SARS-CoV-2 S protein and Tfh activation was assessed the next day by analyzing CD69 and CD154 expression by flow cytometry. The gating strategy used to
identify this population is shown in Figure S3.
In (C)-(E) medians are indicated by a bar. Groups were compared using the Mann-Whitney U test (*p < 0.05; **p < 0.01).
See also Figures S2 and S3.
ll
OPEN ACCESS
6 Cell 184, 1–13, March 4, 2021
Please cite this article in press as: Brouwer et al., Two-component spike nanoparticle vaccine protects macaques from SARS-CoV-2 infec-
tion, Cell (2021), https://doi.org/10.1016/j.cell.2021.01.035
Article
swabs (Figures 6A and S5). In addition to the upper airways,
SARS-CoV-2 S-I53-50NP vaccination significantly decreased
viral loads in the lower airways, as demonstrated by a 275-fold
lower median viral load in the bronchoalveolar lavage (BAL)
(6.5 log10 versus 4.1 log10; p = 0.0095). Viral replication was
also significantly reduced in vaccinated animals. Only two out
of six vaccinated animals (MF5 and MF6) showed detectable
sgRNA in the trachea at 2 dpe, and median viral loads were
160-fold lower than in control animals (4.7 log10 versus 2.5
log10; p = 0.0095). In the nasopharynx, sgRNA remained below
the limit of detection at any of the time points. At 2 dpe, median
sgRNA loads in the vaccinated animals were 5,400-fold lower
than in controls (6.2 log10 versus 2.5 log10; p = 0.0048) (Fig-
ure 6B). In BAL samples, we observed a 120-fold reduction of
Figure 5. Serological responses induced by SARS-CoV-2 S-I53-50NPs in cynomolgus macaques
(A) ELISA endpoint titers for SARS-CoV-2 S-protein-specific IgG. The gray line represents the median titers over time.
(B) SARS-CoV-2 S-protein-specific binding titers at weeks 6 and 12 in macaques compared to those in convalescent humans from the COSCA cohort. Patient
samples were taken 4 weeks after onset of symptoms.
(C) SARS-CoV-2 RBD-specific binding titers at weeks 6 and 12 in macaques compared to those in convalescent humans from the COSCA cohort.
(D) Relative mean fluorescence intensity (MFI) of IgG, IgA, and IgM binding to SARS-CoV-2 S protein measured with a Luminex-based serology assay in serum
samples, nasopharyngeal swabs, and saliva samples. Shown are medians with the shaded areas indicating the interquartile ranges.
(E) SARS-CoV-2 pseudovirus neutralization titers. The gray line represents median titers.
(F) SARS-CoV-2 pseudovirus neutralization titers at weeks 6 and 12 in macaques compared to those in convalescent humans from the COSCA cohort.
(G) SARS-CoV-2 authentic virus neutralization titers at weeks 6 and 12. The bars show the median titers.
In (B), (C), and (F), groups were compared using theMann-Whitney U test (**p < 0.01; ****p < 0.0001). The bars indicate median titers. The dotted lines indicate the
lowest serum dilution.
See also Figure S4.
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median sgRNA at day 3 dpe (4.6 log10 versus 2.5 log10; p =
0.0048) (Figures 6A and 6B).
An anamnestic response after challenge (i.e., an increase in
NAb titers following challenge after vaccination) implies that
vaccination is unable to induce sterilizing immunity. We
observed no increase in median NAb titers in vaccinated ma-
caques at 2, 3, and 6 weeks after challenge, in contrast to the
control animals (Figure S6). Instead, NAb titers generally
continued to wane, suggesting that vaccine-induced immunity
rapidly controlled infection following challenge, preventing a
boost of the immune system.
To assess the potential emergence of viral escape mutants in
macaques after challenge, viral RNA in the challenge inoculum,
nasal swabs at 3 and 5 dpe, and in BAL at 3 dpe was sequenced.
Two main viral variants were identified in the inoculum (V367F in
Figure 6. Protective efficacy of SARS-CoV-2
S-I53-50NPs in cynomolgus macaques
(A) Median RNA viral loads in tracheal swabs (left)
and nasopharyngeal swabs (middle) of control and
vaccinated macaques after challenge. The shaded
area indicates the range. Viral loads in control and
vaccinated macaques after challenge in BAL are
shown (right). Bars indicate median viral loads.
Vertical red dotted lines indicate the day of chal-
lenge. Horizontal dotted lines indicate the limit of
quantification.
(B) sgRNA viral loads in tracheal swabs (left),
nasopharyngeal swabs (middle), and BAL (right) of
control and vaccinated macaques after challenge.
Bars indicate median viral loads. Dotted line in-
dicates the limit of detection.
(C) Emerged viral variants found by viral
sequencing in nasopharyngeal swabs at 3 dpe
(left) and 5 dpe (middle) and BAL at 3 dpe. Colors
indicate the open reading frames (ORFs) in which
mutations were found, as depicted in the legend
below. For a list of all identified variants, see Table
S3. Note that the challenge stock already con-
tained two viral variants, V367F in S protein and
G251V in ORF3a.
(D) Lung CT scores of control and vaccinated
macaques over the course of 14 dpe. CT score
includes lesion type (scored from 0 to 3) and lesion
volume (scored from 0 to 4) summed for each lobe.
(E) Median lymphocyte counts over time in the
blood of control and vaccinated macaques after
challenge. Shaded area indicates the range. Sym-
bols are the sameas indicated in the left panel in (A).
In (A), (B), and (E), groups were compared using
the Mann-Whitney U test (*p < 0.05; **p < 0.01).
See also Figures S5 and S6.
the S protein andG251V in ORF3a), which
were later also found in the nasopharyn-
geal swabs and BAL samples. A median
of six subclonal mutations were found
per sample over all corresponding time
points and anatomical sites, but no major
differences were observed between con-
trol and vaccinated animals (Figure 6C).
The majority of the variants observed in
ORF1ab were mostly missense mutations and consisted of a C
> T nucleotide change (Figure S6D; Table S3). A distinct variant
in the S sequence arose in two vaccinated macaques at day 3 in
the nasopharyngeal swab but disappeared at day 5 post-chal-
lenge, suggesting that no NAb escape mutations emerged in
vaccinated animals (Figure 6C).
Vaccinated cynomolgus macaques have reduced
clinical manifestations
Similar to previous observations (Maisonnasse et al., 2020; Yu
et al., 2020), during the first 14 dpe, all contemporaneous and
historical control animals showed mild pulmonary lesions char-
acterized by nonextended ground-glass opacities (GGOs) de-
tected by chest computed tomography (CT) (Figure 6D). By
contrast, only three out of six vaccinated animals showed low
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CT scores characteristic of mild and nonextended GGOs. Of
note, the vaccinated macaque (MF6) with the highest CT score
at day 14 showed the lowest S protein and RBD binding titers,
the lowest NAb titers, and the highest viral load and sgRNA at
day 5 pe. Whereas all control animals experienced lymphopenia
at 2 dpe, corresponding probably to the installation of the
response to infection, lymphocyte counts remained stable after
challenge for the vaccinated macaques (Figures 6E and S6), in
agreement with the absence of detectable anamnestic
response. Together, these data further support that vaccination
with SARS-CoV-2 S-I53-50NPs reduces the severity of infection.
DISCUSSION
The development and distribution of a protective vaccine is para-
mount to bring the SARS-CoV-2 pandemic to a halt. Over the last
few months, numerous vaccine candidates of different modal-
ities have entered clinical and preclinical studies, including inac-
tivated-virus-, DNA-, mRNA-, vector-, and protein-based vac-
cines (Klasse et al., 2020). Multivalent presentation of RSV and
influenza antigens on two-component self-assembling protein
nanoparticles has generated remarkably potent immune re-
sponses in non-human primates (Boyoglu-Barnum et al., 2020;
Marcandalli et al., 2019). Recently, I53-50NPs presenting the
RBD of SARS-CoV-2 induced potent NAb titers and significantly
decreased viral loads in humanized mice (Walls et al., 2020b).
This RBD-based SARS-CoV-2 vaccine, as well as an RSV vac-
cine using the I53-50 nanoparticle platform, is in clinical develop-
ment (https://www.icosavax.com/), illustrating the feasibility of
large-scale good manufacturing practices (GMP) production.
Here, we show that I53-50NPs presenting 20 copies of prefusion
SARS-CoV-2 S protein induce robust NAb responses in mice,
rabbits, and cynomolgus macaques. Vaccination of the latter
prevented lymphopenia, reduced lung damage, and significantly
reduced viral loads and replication in both the upper and lower
respiratory tract, suggesting that SARS-CoV-2 S-I53-50NPs
could reduce the risk of severe SARS-CoV-2-associated pathol-
ogy in vaccinated humans and control viral shedding and
transmission.
Evidence is mounting that NAb titers are the immunological
correlate of protection for SARS-CoV-2 (Addetia et al., 2020; Yu
et al., 2020), and it is increasingly accepted that a successful
SARS-CoV-2 vaccine will need to induce potent NAb responses.
We observed notable differences in NAb titers by our vaccine
and previously described candidates, although comparisons
maybebiasedbydifferences in vaccination schedules, assay vari-
ability,and inconsistencies indatapresentation.Here,SARS-CoV-
2 S-I53-50NP-vaccinated macaques neutralized authentic virus
with a median ID50 of 4,000 after the final immunization, while
NAb titers induced by adenovirus vector vaccines, including ChA-
dOx1 (van Doremalen et al., 2020) and Janssen (Mercado et al.,
2020), DNA vaccines (Yu et al., 2020) and Inovio (Patel et al.,
2020), and the inactivated vaccines Sinopharm (Wang et al.,
2020) and Sinovacc (Gao et al., 2020), were at least 10-fold lower.
However, NAb titers induced by SARS-CoV-2 S-I53-50NPs were
similar to the Moderna mRNA vaccine (Corbett et al., 2020) and
lower than the Novavax and Clover Biopharmaceuticals protein
vaccines (Guebre-Xabier et al., 2020; Liang et al., 2020).
Besides protecting an individual from COVID-19, a key
component of an effective SARS-CoV-2 vaccine will be its ability
to prevent viral transmission. Hence, sgRNA levels in the upper
and lower airways are valuable endpoints in the evaluation of
vaccine candidates. Similar to the Janssen and Novavax vac-
cines, vaccination with SARS-CoV-2 S-I53-50NPs decreased
median sgRNA to undetectable levels in the upper airways of
all vaccinated animals within 5 dpe, while several other vaccines
were unsuccessful in achieving such an effect (van Doremalen
et al., 2020; Patel et al., 2020; Yu et al., 2020). One should
consider that the Janssen and Novavax studies used 10- to
100-fold lower challenge doses than used here. On the other
hand, our regimen consisted of three immunizations, a number
that may not be practical in the context of large-scale vaccina-
tion campaigns. However, even though three immunizations
were used, the high NAb titers at week 6 indicate that two immu-
nizations may be sufficient to confer protection. As in the Nova-
vax study, the animals here were challenged 2 weeks after the
final immunization (i.e., at peak NAb titer). It is therefore difficult
to draw conclusions on the durability of the protection, but we
note that SARS-CoV-2 memory B cells are expected to remain
stable over a long period of time (Gaebler et al., 2021). Collec-
tively, the rapid decrease in sgRNA levels, the low level of viral
mutations in the S protein, and the absence of an anamnestic
response after challenge emphasize SARS-CoV-2 S-I53-50NP
vaccination’s profound ability to control infection and replication.
We propose two factors thatmay have been responsible for the
potent humoral responses and protective efficacy by SARS-CoV-
2 S-I53-50NPs. First, the high density of antigen on the I53-50NPs
may have facilitated efficient activation of relevant NAb B cell lin-
eages, which is in line with previous studies (Antanasijevic et al.,
2020; Brouwer et al., 2019) and supported by B cell activation ex-
periments described here. Second, by using an S protein that has
been stabilized in the prefusion state, we have likely improved the
conformation of key NAb epitopes (such as the RBD) and
decreased the exposure of non-NAb epitopes. Indeed, it has
recently been shown that introduction of the two appropriately
positioned prolines and removal of the polybasic-cleavage site
significantly improved theprotective ability of anSprotein vaccine
(Amanat et al., 2020). Nonetheless, these mutations alone might
not be sufficient to generate stable trimeric S proteins, and intro-
ducing additional stabilizing mutations, such as the previously
described HexaPro mutations (Hsieh et al., 2020; Juraszek et
al., 2021), may further improve the SARS-CoV-2 S-I53-50NP-
induced humoral responses. Recently, nasal immunization has
been shown to dramatically improve SARS-CoV-2 vaccine effi-
cacy over intramuscular dosing (Hassan et al., 2020). Using this
alternative administration route may allow SARS-CoV-2 S-I53-
50NPs to elicit protective NAb titers in the mucosa and could
advance its protective efficacy toward fully sterilizing immunity.
Limitations of study
The data presented here show that three immunizations with
SARS-CoV-2 S-I53-50NPs can induce protective immunity to a
high-dose SARS-CoV-2 challenge. There are some limitations
in our study that we should note. First, we challenged the ma-
caques 2 weeks after the final immunization, generally corre-
sponding to the peak of NAb titers. We therefore cannot
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ascertain that our vaccine would be as efficacious in the context
of a delayed SARS-CoV-2 exposure. Second, our regimen
included three immunizations (i.e., one more than vaccines
currently in use or under consideration). Although we observed
potent NAb responses after two immunizations, we cannot
draw firm conclusions on the protective efficacy after two immu-
nizations. Finally, recent months have seen the emergence of
novel SARS-CoV-2 strains that may have the potential to evade
NAb responses. Whether our vaccine is able to protect against
these mutants warrants further investigation.
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Minimap2 Li, 2018 https://github.com/lh3/minimap2
Varscan Koboldt et al., 2012 http://varscan.sourceforge.net/
Longshot Edge and Bansal, 2019 https://github.com/pjedge/longshot





ImageQuant TL 8.2 image analysis software GE Healthcare N/A
Other
EasySpray PepMap RSLC C18 column
(75 mm x 75 cm)
Thermo Fisher Scientific Cat# ES805
C18 ZipTip Merck Milipore Cat# ZTC18S008
Vivaspin 500, 3 kDa MWCO,
Polyethersulfone
Sigma-Aldrich Cat# GE28-9322-18
PepMap100 C18 3UM 75UMx2CM
Nanoviper
Thermo Scientific Cat# 164946
Ni-NTA agarose QIAGEN Cat# 30210
Ni-NTA HighSorb plates QIAGEN Cat# 35061
NuPAGE 4-12% Bis-Tris gels Thermo Fisher Cat# NP0321BOX
Superose 6 increase 10/300 GL Sigma-Aldrich Cat# GE29-0915-96
Econo-column chromatography columns BIO RAD Cat# 7371512
NGC chromatography system BIO RAD N/A
Octet K2 system Sartorius (FortéBio) N/A
Octet Biosensors: Protein A Sartorius (FortéBio) Cat# 18-5010
Vivaspin 20, 100.000 kDa MWCO,
Polyethersulfone
Sigma-Aldrich Cat# GE28-9323-63
Nucleobond Xtra Maxi kit Macherey-Nagel Cat# 740414.50
Fast Digest BamHI Thermo Scientific Cat# FD0054
Fast Digest Green buffer 10x Thermo Scientific Cat# B72
Fast Digest PstI Thermo Scientific Cat# FD0614
Magplex Microspheres Luminex Cat# MC10043-01
Streptavidin-PE Thermo Fisher Scientific Cat# 12-4317-87
Bioplex 200 Bio-Rad Cat# 171000205
FreeStyle 293 Expression medium Thermo Scientific Cat# 12338018
DMEM Sigma-Aldrich Cat# D6429-500ML
Glutamax supplement Thermo Fisher Cat# 35050061
High-binding plates: Half-area 96-well
polystyrene high-binding microplate
Greiner Cat# 675061
Steritop Filter Units Merckmillipore Cat# C3239
Glomax Turner BioSystems Model# 9101-002
Microplate 96 well half area white Greiner bio-one Cat# 675074
VTM medium CDC, DSR-052-01 https://www.cdc.gov/coronavirus/
2019-ncov/downloads/
Viral-Transport-Medium.pdf
(Continued on next page)
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Further information and requests for resources and reagents should be directed to and will be fulfilled by the lead contact, Rogier W.
Sanders (r.w.sanders@amsterdamumc.nl).
Materials availability
All reagents will be made available on request after completion of a Materials Transfer Agreement.
Data and code availability
The raw data supporting the findings of the study are available from the corresponding authors upon reasonable request.
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Cell lines
HEK293F (Life Technologies) and HEK293T (ATCC CRL-11268) are human embryonic kidney cell lines transformed for increased
production of recombinant protein or retrovirus. HEK293F cells are adapted to grow in suspension. HEK293F cells were cultured
at 37C with 8% CO2 and shaking at 125 rpm in 293FreeStyle expression medium (Life Technologies). HEK293T cells were cultured
at 37Cwith 5%CO2 in flasks with DMEM supplemented with 10% fetal bovine serum (FBS), streptomycin (100 mg/mL) and penicillin
(100 U/mL). VeroE6 (ATCC CRL-1586) is a kidney epithelial cell from African green monkeys. VeroE6 cells were cultured at 37Cwith
5% CO2 in DMEM supplemented with or without streptomycin (100 mg/mL) and penicillin (100 U/mL) and with or without 5 or 10%
FBS, and with or without TPCK-trypsin. HEK293T/ACE2 cells (Schmidt et al., 2020) are a human embryonic kidney cell line express-
ing human angiotensin-converting enzyme 2. HEK293T/ACE2 cells were cultured at 37Cwith 5% CO2 in flasks with DMEM supple-
mented with 10%FBS, streptomycin (100 mg/mL) and penicillin (100 U/mL). Ramos is a human Burkitt’s lymphoma cell line that has B
lymphocyte characteristics. Ramos B cells were cultured at 37C with 5% CO2 in RPMI supplemented with 10% FBS, streptomycin
(100 mg/mL) and penicillin (100 U/mL).
Cynomolgus macaques
Female cynomolgus macaques (Macaca fascicularis), aged 56-66 months and originating fromMauritian AAALAC certified breeding
centers were used in this study. All animals were housed in IDMIT infrastructure facilities (CEA, Fontenay-aux-roses), under BSL-2
and BSL-3 containment when necessary (Animal facility authorization #D92-032-02, Préfecture des Hauts de Seine, France) and in
compliance with European Directive 2010/63/EU, the French regulations and the Standards for Human Care and Use of Laboratory
Animals, of theOffice for Laboratory AnimalWelfare (OLAW, assurance number #A5826-01, US). The protocols were approved by the
institutional ethical committee ‘‘Comité d’Ethique en Expérimentation Animale duCommissariat à l’Energie Atomique et aux Energies
Alternatives’’ (CEtEA #44) under statement number A20-011. The study was authorized by the ‘‘Research, Innovation and Education
Ministry’’ under registration number APAFIS#24434-2020030216532863v1.
Continued
REAGENT or RESOURCE SOURCE IDENTIFIER
RPMI Medium 1640 GIBCO Cat# 21875-034
Hanks’ Balanced Salt Solution (HBSS) GIBCO Cat# 14175-053
FACS Aria-II SORP BD biosciences N/A
LSR Fortessa BD biosciences N/A
Amersham Typhoon Biomolecular Imager GE Healthcare Amersham Typhoon Biomolecular Imager
BD micro-fine+; U-100 Insulin 0.5 ml; 0,33
(29G)x12,7 mm
BD biosciences Cat# 037-7614
Microvette CB300 K2E Sarstedt Cat# 16.444.100
HEPES (1M, GIBCO) Thermofisher scientific Cat# 15630106
Greiner CELLSTAR 96 well plates round
bottom clear wells
Merck Cat# M9436
Lemo21 (DE3) New England Biolabs Cat# C2528J
Ni Sepharose 6 FF Cytiva Cat#17531808
AKTA Avant150 FPLC system Cytiva N/A
Superdex 200 Increase SEC column Cytiva Cat# 28-9909-44
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Rabbits
Female New Zealand White rabbits of 2.5-3 kg from multiple litters were used. Animals were sourced and housed at Covance
Research Products, Inc. (Denver, PA, USA) and immunizations were performed under permits with approval number C0084-20. Im-
munization procedures complied with all relevant ethical regulations and protocols of the Covance Institutional Animal Care and Use
Committee.
Mice
Female BALB/cAnNCrl mice, aged 8 weeks, were ordered from Charles River Laboratories and housed at the Animal Research Insti-
tute Amsterdam under BSL-2 conditions. All experiments were performed in accordance with the Dutch Experiment on Animals Act
and were approved by the Animal Ethics Committee of the Amsterdam UMC (Permit number 17-4045).
Patient sera
Sera were collected from male and female patients aged between 18 and 75 years through the COVID-19 Specific Antibodies
(COSCA) study, which was performed at the Amsterdam University Medical Centre, location AMC, the Netherlands under approval
of the local ethical committee of the AMC (NL 73281.018.20) (Brouwer et al., 2020).
METHOD DETAILS
Construct design
Tocreate theSARS-CoV-2S-I53-50A.1NT1construct, the previouslydescribedpPPI4 plasmid encoding theprefusion stabilizedSARS-
CoV-2Sprotein (Brouwer et al., 2020)wasdigestedwithPstI andBamHI and ligated inaPstI-BamHI-digestedpPPI4plasmidencodinga
modified I53-50A.1NT1 sequence. The original I53-50A.1NT1 plasmid was described previously (Brouwer et al., 2019). Modifications
constitute the introduction of GSLEHHHHHH after the final residue to introduce a C-terminal histidine-tag. To generate S proteins for
FACS analyses, the prefusion S protein sequence was cloned into a pPPI4 backbone encoding a I53-50A.1NT1 sequence that had
anAvi- andhistidine-tagafter thefinal residue.TheRBDprobewasgeneratedbydigesting thisplasmidwithPstI-BamHIand introducing,
byGibson assembly, a gene encoding theRBD (residues 319-541) directly downstreamof a TPA leader sequence. For ELISAs, Luminex
assays, and ELISpots, histidine-tagged versions of SARS-CoV-2 S protein and RBDwere produced by cloning the aforementioned se-
quences into a pPPI4 plasmid containing a hexahistidine tag using PstI and BamHI digestion and ligation.
Protein expression and purification
All constructs were expressed by transient transfection of HEK293F cells (Invitrogen) maintained in Freestyle medium (Life Technol-
ogies) at a density of 0.8-1.2 million cells/mL. On the day of transfection, a mix of PEImax (1 mg/mL) with expression plasmids
(312.5 mg/L) in a 3:1 ratio in OptiMEM (GIBCO) were added to the cells. Six days post transfection, supernatants were centrifuged
for 30 min at 4000 rpm, filtered using 0.22 mm Steritop filters (Merck Millipore), and subjected to affinity purification using Ni-NTA
agarose beads. Protein eluates were then concentrated and buffer exchanged to PBS using Vivaspin filters with the appropriate mo-
lecular weight cutoff (GE Healthcare). Protein concentrations were determined by the Nanodrop method using the proteins peptidic
molecular weight and extinction coefficient as determined by the online ExPASy software (ProtParam).
I53-50B.4PT1 expression and purification
Lemo21 (DE3) (NEB) cells expressing I53-50B.4PT1 were grown in a 10L BioFlo 320 Fermenter (Eppendorf) or a 2L shake flask. Cells
were grown in LB (10 g Tryptone, 5 g Yeast Extract, 10 g NaCl) at 37C to an OD600 of 0.8. After the cells were induced with 1 mM of
IPTG, temperature was reduced to 18C and cells were grown for 16h. The cells were then lysed in 50mM Tris, 500mMNaCl, 30mM
imidazole, 1mMPMSF, 0.75%CHAPS using aMicrofluidics M110P at 18,000 psi. Lysate was centrifuged at 24,000 g for 30minutes.
Clarified lysate was next applied to a Ni Sepharose 6 FF column (Cytiva) linked to an AKTA Avant150 FPLC system (Cytiva) for im-
mobilized metal affinity chromatography. I53-50B.4PT1 was eluted using a 30 mM to 500mM imidazole linear gradient in 50 mM Tris
pH 8, 500mMNaCl and 0.75%CHAPS. Fractions containing I53-50B.4PT1 were pooled, concentrated using centrifugal filters with a
10,000 kDa cutoff (Millipore), sterilized and applied to a Superdex 200 Increase 10/300 (Cytvia) for further purification. Batches were
tested for endotoxin levels before use.
SARS-CoV-2 S-I53-50NP assembly
Ni-NTA eluates of SARS-CoV-2 S-I53-50A.1NT1 (expressed as described above) were buffer exchanged to Tris-buffer-saline (TBS),
sterile filtered (0.22 mm) and applied to a Superose 6 increase 10/300 GL column (GE healthcare) linked to a NGC chromatography
system (Bio-Rad) in TBS supplemented with 5% glycerol. Size exclusion fractions between 12-14 mL were pooled and an equimolar
amount of I53-50B.4PT1was added. After an overnight incubation at 4C, the assemblymixwas applied to a Superose 6 increase 10/
300 GL column in TBS+5% glycerol to remove unassembled components. Fractions corresponding to assembled SARS-CoV-2 S-
I53-50NPs (8.5-9.5 mL) were collected and concentrated using Vivaspin columns with a molecular weight cutoff of 10,000 kDa (GE
Healthcare). Protein concentrations were determined by the Nanodrop method using the proteins peptidic molecular weight and
extinction coefficient as determined by the online ExPASy software (ProtParam).
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BN-PAGE analysis
BN-PAGE was performed as described previously (de Taeye et al., 2015). Briefly, 2.5 mg of S protein was mixed with loading dye and
run on a 4%–12% Bis-Tris NuPAGE gel (Invitrogen).
Negative-stain EM
SARS-CoV-2 S-153-50NPswere added to carbon-covered 400mesh copper grids and stainedwith 2%uranyl formate. Micrographs
were imaged on a Tecnai F12 Spirit microscope with a 4k FEI Eagle CCD. Leginon (Potter et al., 1999) and Appion (Lander et al., 2009)
were used to collect and process micrographs.
BLI assay
SARS-CoV-2 S-I53-50A.1NT1 and SARS-CoV-2 S-I53-50NP were diluted to 100 nM and 5nM, respectively, in BLI running buffer
(PBS/0.1% bovine serum albumin/0.02% Tween20) and antibody binding was assessed using a ForteBio Octet K2. The binding as-
says were performed at 30C and with agitation set at 1000 rpm. Antibody was loaded on protein A sensors (ForteBio) at 10 mg/mL in
running buffer until a binding threshold of 1 nm was reached. Association and dissociation were measured for 300 s.
Glycopeptide analysis by liquid chromatography-mass spectrometry
Gycopeptide analysis was essentially performed as described previously (Watanabe et al., 2020). A 30 mg aliquot of SARS-CoV-2 S-
I53-50A.1NT1 was denatured, alkylated, reduced and cleaved by the proteases trypsin, chymotrypsin and alpha-lytic protease.
Clean-up of the resulting peptide/glycopeptides was performed using C18 Zip-tips and the sample was analyzed by nanoLC-ESI
MSwith an Easy-nLC 1200 (Thermo Fisher Scientific) system coupled to a Fusionmass spectrometer (Thermo Fisher Scientific) using
higher energy collision-induced dissociation (HCD) fragmentation. Peptides were separated using an EasySpray PepMap RSLC C18
column (75 mm 3 75 cm). Glycopeptide fragmentation data were extracted from the raw file using ByonicTM (Version 3.5) and Byo-
logicTM software (Version 3.5; Protein Metrics Inc.).
Generation of B cells that stably express COVID-specific B cell receptors
The B cell specific expression plasmid was constructed by exchanging the gl2-1261 gene of the pRRL EuB29 gl2-1261
IgGTM.BCR.GFP.WPRE plasmid (McGuire et al., 2014) with heavy and light chain genes of either COVA1-18 and COVA2-15 using
Gibson assembly (Integrated DNA Technologies). The production of lentivirus in HEK293T and the subsequent transductionwas con-
ducted as described elsewhere (ter Brake et al., 2006). In short, lentiviruses were produced by co-transfecting the expression
plasmid with pMDL, pVSV-g and pRSV-Rev into HEK293T cells using lipofectamine 2000 (Invitrogen). Two days post transfection,
IgM-negative Ramos B cells cultured in RPMI (GIBCO) supplemented with 10% fetal calf serum, streptomycin (100 mg/mL)
and penicillin (100 U/mL) (RPMI++) were transduced with filtered (0.45 mm) and concentrated (100 kDa molecular weight cutoff,
GE Healthcare) HEK293T supernatant. Seven days post transduction, BCR-expressing B cells were FACS sorted on IgG and
GFP double-positivity using a FACS Aria-II SORP (BD biosciences). B cells were then expanded and cultured indefinitely.
B cell activation assay
B cell activation experiments of SARS-CoV-2 S protein-specific Ramos B cells were performed as previously described (Brouwer
et al., 2019; Sliepen et al., 2019). In short, 4 million cells/mL in RPMI++ were loaded with 1.5 mM of the calcium indicator Indo-1 (In-
vitrogen) for 30 min at 37C, washed with Hank’s Balance Salt Solution supplemented with 2 mM CaCl2, followed by another incu-
bation of 30 min at 37C. Antigen-induced Ca2+ influx of COVID-specific B cells were monitored on a LSR Fortessa (BD Biosciences)
by measuring the 379/450 nm emission ratio of Indo-1 fluorescence upon UV excitation. Following 30 s of baseline measurement,
aliquots of 1 million cells/mL were then stimulated for 100 s at RT with either 5 mg/mL, 1 mg/mL, 200 ng/mL or 40 ng/mL of SARS-
CoV-2 S-I53-50A.1NT1 or the equimolar amount presented on I53-50NPs. Ionomycin (Invitrogen) was added to a final concentration
of 1 mg/mL to determine the maximum Indo-1-fluorescence. Kinetics analyses were performed using FlowJo v10.7.
Animals and study designs
Cynomolgus macaques were randomly assigned in two experimental groups. The vaccinated group (n = 6) received 50 ug of SARS-
CoV-2 S-I53-50NP adjuvanted with 500 mg of MPLA liposomes (Polymun Scientific, Klosterneuburg, Austria) diluted in PBS at weeks
0, 4 and 10, while control animals (n = 4) received no vaccination. Vaccinated animals were sampled in blood, nasal swabs and saliva
at weeks 0, 2, 4, 6, 8, 10 and 12. At week 12, all animals were exposed to a total dose of 106 pfu of SARS-CoV-2 virus (hCoV-19/
France/ lDF0372/2020 strain; GISAID EpiCoV platform under accession number EPI_ISL_406596) via the combination of intranasal
and intra-tracheal routes (0,25 mL in each nostril and 4,5 mL in the trachea, i.e., a total of 5 mL; day 0), using atropine (0.04 mg/kg) for
pre-medication and ketamine (5 mg/kg) with medetomidine (0.042mg/kg) for anesthesia. Saliva, as well as nasopharyngeal, tracheal
and rectal swabs, were collected at days 1, 2, 3, 4, 5, 6, 10, 14 and 21 days past exposure (dpe) while blood was taken at days 2, 4, 6,
10, 14 and 21 dpe. Bronchoalveolar lavages (BAL) were performed using 50mL sterile saline on 3 dpe. A single BALwas performed at
3 dpe in order to be close to the peak of viral replication and to be able to observe a difference between the vaccinated and control
groups. In our earlier study (Maisonnasse et al., 2020), we found that at later time-points, viral loads in the BAL were very low or nega-
tive. Chest CT was performed at baseline and on 3, 7 and 14 dpe in anesthetized animals using tiletamine (4 mg/kg) and zolazepam
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(4 mg/kg). Blood cell counts, haemoglobin and hematocrit were determined from EDTA blood using a HMX A/L analyzer (Beckman
Coulter).
Female New ZealandWhite rabbits were given two intramuscular immunizations, one in each quadricep, at weeks 0, 4, and 12. The
immunization mixture involved 39 mg of SARS-CoV-2-S-I53-50NPs (equal to 30 mg of SARS-CoV-2-S) formulated 1:1 in Squalene
Emulsion adjuvant (Polymun, Klosterneuburg, Austria). The rabbits were bled on the day of immunization and then at weeks 2, 4,
6, and 14.
Female Balb/cAnNCrl mice received subcutaneous immunizations into the neck skin-fold at weeks 0, 4, and 12. The immunization
mixture contained 13 mg of SARS-CoV-2-S-I53-50NPs (equal to 10 mg of SARS-CoV-2-S) adjuvanted with 50 mg of polyinosinic-poly-
cytidylic acid (Poly-IC; Invivogen). Blood was collected at weeks 1, 2, 6 and 14. Two out of eight mice were sacrificed at week 6 to
allow interim analysis of the induced humoral response.
Patient samples
Patients with at least one nasopharyngeal swab positive for SARS-CoV-2 as determined by qRT-PCR (Roche LightCycler480, targeting
the Envelope-gene 113bp) were included. Patients using immunosuppressive mediation (equivalent of > 7.5 mg prednisolone) were
excluded from the study. Included patients signed written informed consent forms. A venipuncture was performed to obtain blood in
Acid Citrate Dextrose tubes for serum collection approximately four weeks after onset of COVID-19 symptoms (Brouwer et al., 2020).
ELISAs
Ni-NTA plates (QIAGEN) were loaded with 2 mg/mL of SARS-CoV-2 S protein in TBS for 2 h at RT. Next, washed plates were blocked
for 1 hwith TBS/2% skimmedmilk. Four-fold serial dilutions of inactivated sera, starting from a 1:200 dilution for mice and rabbit sera,
and 1:100 dilution for macaque sera, were added in TBS/2% skimmedmilk/20% sheep serum and incubated for 2 h at RT. Following
plate washing, a 1:3000 dilution of secondary antibody in TBS/2% skimmed milk was added for 1 h at RT. For mice, rabbit and ma-
caque sera horseradish peroxidase (HRP)-labeled goat anti-mice IgG, HRP-labeled goat anti-rabbit IgG and HRP-labeled goat anti-
human IgG (Jackson Immunoresearch) was used, respectively. Finally, after washing plates with TBS/0.05% Tween-20, developing
solution (1%3,30,5,50-tetranethylbenzidine (Sigma-Aldrich), 0.01%H2O2, 100mMsodium acetate and 100mMcitric acid) was added
to each well and a colorimetric endpoint was obtained by adding 0.8 M H2SO4 after 1.5 min. Binding endpoint titers were determined
using a cutoff of 5x background.
As affinity differences between species-specific secondary Abs may bias comparisons between endpoint titers of macaque and
convalescent human sera, we used a different ELISA setup to compare S protein and RBD binding responses. Specifically, ELISA
binding responses are compared to a standard curve of species-specific polyclonal IgG so that a semiquantitative measure
of specific IgG concentrations can be obtained. High-binding plates were direct-coated overnight at 4C with 2 mg/mL of SARS-
CoV-2 S or 0.4 mg/mL of SARS-CoV-2 RBD in PBS. For capture of the standard curve (i.e., macaque and human polyclonal IgG),
plates were coated with 1:2000 (for capture of polyclonal macaque IgG) or 1:1000 (for capture of polyclonal human IgG) of goat
anti-Human IgG l and k (Southern Biotech). The next day, plates were washed with TBS than contained 0.05% Tween-20 (TBST)
and blocked for 1 h with Casein buffer (Thermo Fisher Scientific). A 1:100, 1:1000 and 1:10,000 dilution of macaque or human serum
in Casein buffer were then added to the wells containing S protein or RBD. Five-fold serial dilutions of polyclonal macaque (Molecular
Innovations) or human IgG, starting at a concentration of 1 mg/mL, were added to wells containing the coated goat anti-Human IgG l
and k. Standards and samples were applied in duplicate. Following a 1 h incubation at RT, the plates were washed with TBST and
secondary antibody diluted in Casein buffer was added for 1 h. For the plates containing human sera and standard, a 1:3000 dilution
of HRP-labeled goat anti-human IgG (Jackson Immunoresearch) was used. For plates containing macaque sera and standard, a
1:50,000 dilution of biotinylated mouse anti-monkey IgG was used (Southern Biotech), followed by a 1 h incubation with a 1:3000
dilution of HRP-labeled streptavidin (Biolegend) in Casein. Finally, after washing plates with TBST, developing solution (1%
3,30,5,50-tetranethylbenzidine (Sigma-Aldrich), 0.01% H2O2, 100 mM sodium acetate and 100 mM citric acid) was added to each
well and a colorimetric endpoint was obtained by adding 0.8 M H2SO4 after 5 min. OD450-values that fell within the linear range of
the standard curve were fitted and the concentration of SARS-CoV-2 S protein and RBD-specific IgG was determined.
Pseudovirus neutralization assay
To generate SARS-CoV-2 pseudovirus, HEK293T cells (ATCC, CRL-11268) were transfected with a pHIV-1NL43DENV-NanoLuc re-
porter virus plasmid and a SARS-CoV-2-SD19 plasmid (Schmidt et al., 2020). Cell supernatant containing the pseudoviruses was har-
vested 48 h post transfection, centrifuged for 5 min at 500 x g and sterile filtered through a 0.22 mm pore size PVDF syringe filter. For
neutralization assays HEK293T expressing the SARS-CoV-2 receptor ACE2 (HEK293T/ACE2) were cultured in DMEM (GIBCO), sup-
plemented with 10% FBS, penicillin (100 U/mL), and streptomycin (100 mg/mL).To determine the neutralization activity in serum,
saliva or nasopharyngeal samples, HEK293T/ACE2 cells were first seeded in 96-well plates coated with 50 mg/mL poly-l-lysine at
a density of 2x104/well in the culture medium described above but with GlutaMax (GIBCO) added. The next day, duplicate serial di-
lutions of heat inactivated samples were prepared in the same medium as used for seeding of cells and mixed 1:1 with pseudovirus.
Thismixture was incubated at 37C for 1 h before adding it to the HEK293T/ACE2 cells in a 1:1 ratio with the cell culturemedium. After
48 h, the cells were lysed and lysate was transferred into half area 96-well whitemicroplates (Greiner bio-one). Luciferase activity was
measured in the lysates using theNano-Glo Luciferase Assay System (Promega) with aGlomax system (Turner BioSystems). Relative
ll
OPEN ACCESS
Cell 184, 1–13.e1–e11, March 4, 2021 e8
Please cite this article in press as: Brouwer et al., Two-component spike nanoparticle vaccine protects macaques from SARS-CoV-2 infec-
tion, Cell (2021), https://doi.org/10.1016/j.cell.2021.01.035
Article
luminescence units (RLU) were normalized to those from cells infected with SARS-CoV-2 pseudovirus in the absence of sera/saliva/
swabs. Neutralization titers (ID50-values) were determined as the serum dilution at which infectivity was inhibited by 50%.
Authentic virus neutralization assay
Serum samples were tested for their neutralization activity against SARS-CoV-2 (German isolate; GISAID ID EPI_ISL 406862; Euro-
pean Virus Archive Global #026V-03883) as described previously (Okba et al., 2020). In short, serum samples were serially diluted in
50 mL Opti-MEM I (GIBCO), supplemented with GlutaMAX (GIBCO) and penicillin (100 U/mL). Serum dilutions were mixed with 400
plaque-forming units of virus to a total of 100 mL. This mixture was incubated at 37C for 1 h. After incubation, the mixtures were put
on Vero-E6 cells (ATCC CRL-1586) and incubated for 1 h. Cells were then washed, Opti-MEM I supplemented with GlutaMAX
(GIBCO) was added, and incubated for 8 h. Cells were fixed with 4% formaldehyde in PBS and stained with polyclonal rabbit
anti-SARS-CoV Ab (Sino Biological) and secondary Alexa488 conjugated goat-anti-rabbit Ab (Invitrogen). Plates were scanned on
the Amersham Typhoon Biomolecular Imager (channel Cy2; resolution 10 mm; GE Healthcare). Data was analyzed using ImageQuant
TL 8.2 image analysis software (GE Healthcare).
Protein coupling to Luminex beads
Proteins were covalently coupled to Magplex beads (Luminex Corporation) using a two-step carbodiimide reaction and a ratio of
75 mg protein SARS-CoV-2 S protein to 12,5 million beads. Magplex beads (Luminex Corporation) were washed with 100 mMmono-
basic sodium phosphate pH 6.2, activated for 30min on a rotor at RT by addition of Sulfo-N-Hydroxysulfosuccinimide (Thermo Fisher
Scientific) and 1-Ethyl-3-(3-dimethylaminopropyl) carbodiimide (Thermo Fisher Scientific). The activated beads were washed three
times with 50 mMMES pH 5.0 and added to SARS-CoV-2 S protein which was diluted in 50 mMMES pH 5.0. The beads and protein
were incubated for 3 h on a rotator at RT. Afterward, the beads were washed with PBS and blocked with PBS containing 0.1% BSA,
0.02% Tween-20 and 0.05%Sodium Azide at pH 7.0 for 30 min on a rotator at RT. Finally, the beads were washed and stored in PBS
containing 0.05% Sodium Azide at 4C and used within 3 months.
Luminex assays
50 mL of a working bead mixture containing 20 beads per mL was incubated overnight at 4C with 50 mL of diluted serum, saliva or
nasopharyngeal swab. Pilot experiments determined the optimal dilution for detection of SARS-CoV-2 S protein-specific IgG, IgA
and IgM antibodies in serum to be 1:50,000, for the detection of antibody binding to FcgRIIa, FcgRIIIa and C1q in serum at 1:500
and for detection of S protein-specific IgG and IgA in saliva and nose fluid at 1:20. Plates were sealed and incubated on a plate shaker
overnight at 4C. The next day, plates were washed with TBS containing 0.05% Tween-20 (TBST) using a hand-held magnetic sepa-
rator. Beads were resuspended in 50 mL of Goat-anti-human IgG-PE, Goat-anti human IgA-PE or Mouse-anti human IgM-PE (South-
ern Biotech) and incubated on a plate shaker at RT for 2 h. For C1q binding, beads were resuspended in 50 mL purified human C1q
(Complement Technology, Inc.), whichwas biotinylated and conjugated to Streptavidin-PE. For the detection of FcgRIIa and FcgRIIIa
binding, beads were resuspended in 50 mL biotinylated human FcgRIIa and FcgRIIIa ectodomain dimers (courtesy of Bruce Wines
and Mark Hogarth) for 2 h incubation, after which the beads were washed with TBST and then incubated with 50 mL Streptavidin-PE
(Invitrogen) on a plate shaker for 1 h. Afterward, the beads were washed with TBST and resuspended in 110 mL Bioplex sheath fluid
(Bio-Rad). The beads were agitated for a few minutes on a plate shaker at RT and then readout was performed on the Bioplex 200
(Bio-Rad). Resulting mean fluorescence intensity (MFI) values were corrected by subtraction of MFI values from buffer and beads
only wells. Relative MFI values were obtained by dividing the MFI by the background MFI at week 0. Reproducibility of the results
was confirmed by performing replicate runs.
SARS-CoV-2 S protein-specific CD4- and cTfh cell analysis using an activation induced marker (AIM) assay
Cryopreserved macaque PBMCs from 2 weeks after final immunization (week 12) were thawed and counted. 1x106 cells per condi-
tion were plated in 96 U-shape well plates (CELLSTAR, Kremsmünster) and rested for 2-3 h in RPMI (GIBCO), supplemented with
10% FBS, 1mM HEPES (GIBCO), penicillin (100 U/mL), and streptomycin (100 mg/mL). Subsequently, cells were incubated with
0.5 mg/mL anti-CD40 (Miltenyi Biotec) for 15 min at 37C, to prevent downregulation of CD40 ligand (CD40L) by blocking CD40-
CD40L interaction. PBMCswere stimulated for 18 h at 37Cwith 5mg/mL SARS-CoV-2 S protein. As a negative control no stimulants
were added, and as a positive control 1 mg/mL Staphylococcal enterotoxin B was used. Thereafter, PBMCs were washed using
FACS buffer (PBS, supplemented with 1% FBS). PBMCs were then incubated with the cTfh-specific chemokine receptor antibody
CXCR5 PE-Cy7 (clone MU5UBEE; eBioscience) for 10 min at 37C. Next, the following antibodies and viability dye were incubated
with PBMCs at RT for 20 min: anti-CD3 BUV395 (clone SP34-2; BD Biosciences), anti-CD4 BUV495 (clone SK3; BD Biosciences),
anti-CD154 BV421 (clone TRAP1; BD Biosciences), anti-CD69 BV785 (clone FN50; BD Biosciences), anti-4-1BB APC (clone 4B4-
1; Biolegend) and LiveDead-eF780 (eBioscience). Cells were washed twice with FACS buffer before acquisition on the BD LSR II For-
tessa 5 lasers flow cytometer (BD biosciences). Analysis was performed on FlowJo v.10.7.1.
SARS-CoV-2 S protein and RBD-specific B cell analysis
Biotinylated SARS-CoV-2 S protein and RBD were conjugated to streptavidin-bound fluorophores. Briefly, the biotinylated proteins
were incubated for a minimum of 1 h at 4C with the streptavidin-conjugates AF647 (Biolegend), BV421 (Biolegend) and BB515 (BD
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Biosciences) at a 1:2 protein to fluorochrome ratio. The fluorescent probes were incubated for at least 10 min with 10mMbiotin (Gen-
eCopoeia) to saturate the unconjugated streptavidin-fluorochrome complexes. Cryopreserved macaque PBMCs from 2 weeks after
final immunization (week 12) were thawed and counted. 5x106 cells were stained for 30 min at 4C with the fluorescent probes, a
viability marker (LiveDead-eF780, eBiosciences) and the following B cell-specific antibodies: anti-CD20-PE-CF594 (clone 2H7;
BD Biosciences), anti-IgG-PE-Cy7 (clone G18-145;BD Biosciences), anti-CD27-PE (clone M-T271; BD Biosciences), and anti-
IgM-BV605 (clone MHM-88; Biolegend). Cells were washed twice with FACS buffer and acquired on the FACS-ARIA-SORP 4 laser
(BD Biosciences). Analysis was performed on FlowJo v.10.7.1.
Viruses and cells
For the cynomolgus macaque challenge study, SARS-CoV-2 virus (hCoV-19/France/ lDF0372/2020 strain; GISAID EpiCoV platform
under accession number EPI_ISL_406596) was isolated by the National Reference Center for Respiratory Viruses (Institut Pasteur,
Paris, France) (Lescure et al., 2020). Briefly, Vero E6 cells were cultured in DMEM + 5% FBS. PCR-positive sample from patient 0371
was diluted 1:2 with DMEMwith antibiotics but without FBS and supplemented with 1ug/ml trypsin-TPCK (Sigma-Aldrich), added to
the cells and incubated one hour at 37C. The inoculum was then replaced with DMEM medium containing antibiotics and 1mg/ml
trypsin-TPCK at 37C. Three days later, clear cytopathogenic effects were observed and RT-qPCR was performed to detect pres-
ence of virus. Culture supernatant was harvested, aliquoted and stored at 80C.
Before the challenge experiment, virus stocks were first subjected to an additional passage on Vero E6 cells in DMEM (GIBCO)
without FBS, supplemented with penicillin (100 U/mL), streptomycin (100 mg/mL), and 1 mg/mL TPCK-trypsin at 37C in a humidified
CO2 incubator. Virus was then titrated on Vero E6 cells by plaque reduction assay.
Virus quantification in cynomolgus macaque samples
Upper respiratory (nasopharyngeal and tracheal) and rectal specimens were collected with swabs (Viral Transport Medium, CDC,
DSR-052-01). Tracheal swabs were performed by insertion of the swab above the tip of the epiglottis into the upper trachea at
approximately 1.5 cm of the epiglottis. All specimens were stored between 2C and 8C until analysis by RT-qPCR with a plasmid
standard concentration range containing an RdRp gene fragment including the RdRp-IP4 RT-PCR target sequence. SARS-CoV-2 E
gene subgenomic mRNA (sgmRNA) levels were assessed by RT-qPCR using primers and probes previously described (Corman
et al., 2020; Wölfel et al., 2020): leader-specific primer sgLeadSARSCoV2-F CGATCTCTTGTAGATCTGTTCTC, E-Sarbeco-R primer
ATATTGCAGCAGTACGCACACA and E-Sarbeco probe HEX-ACACTAGCCATCCTTACTGCGCTTCG-BHQ1. The protocol
describing the procedure for the detection of SARS-CoV-2 is available on the WHO website (https://www.who.int/docs/
default-source/coronaviruse/real-time-rt-pcr-assays-for-the-detection-of-sars-cov-2-institut-pasteur-paris.pdf?
sfvrsn=3662fcb6_2).
Chest computed tomography and image analysis
Acquisition was done using a computed tomography (CT) system (Vereos-Ingenuity, Philips). Animals were anesthetized and put in a
supine position. Body temperature, oxygen saturation and heart rate were monitored. The collimation of the CT detector was 64 3
0.6 mm, with a 120 kV tube voltage and around 120mA intensity. The intensity was regulated by dose optimization tools (Dose Right,
Z-DOM, 3D-DOM; Philips Healthcare). The reconstructed CT images had a slice thickness of 1.25 mm, with an interval of 0.25 mm.
Lesions were defined, by internationally standard nomenclature, as ground glass opacity, crazy-paving pattern, consolidation or
pleural thickening (Pan et al., 2020; Shi et al., 2020) (none, 0; GGO, 1; pleural thickening, 1; crazy-paving pattern, 3; consolidation,
3). Lesions and scoring were assessed in each lung lobe blindly and independently by two persons and final results were made by
consensus. Overall CT scores include the lesion type, scored from 0 to 3 (None, 0; Slight, 1; Mild, 2; Severe, 3) and lesion volume,
scored from 0 to 4 (None, 0; < 25%of the lobe, 1; 25 < x < 50%of the lobe, 2; 50 < x < 75%of the lobe, 3; 75 < x < 100% of the lobe; 4)
and summed for each lobe.
ELISpot assays
IFNg ELISpot assay of PBMCs was performed using the Monkey IFNg ELISpot PRO kit (Mabtech Monkey IFNg ELISPOT pro,
#3421M-2APT) according to the manufacturer’s instructions. PBMCs were plated at a concentration of 200,000 cells per well and
were stimulated with SARS-CoV-2 S protein at a final concentration of 5 mg/mL. Plates were incubated for 42 h at 37C in an atmo-
sphere containing 5%CO2, then washed 5 times with PBS and incubated for 2 h at 37
Cwith a biotinylated anti-IFNg antibody. After
5 washes, spots were developed by adding 0.45 mm-filtered ready-to-use BCIP/NBT-plus substrate solution and counted with an
automated ELISpot reader ELRIFL04 (Autoimmun Diagnostika GmbH, Strassberg, Germany). Spot forming units (SFU) per
1.0x106 PBMCs are means of duplicates for each animal.
Viral sequencing
30 RNA samples from nasal swabs and bronchoalveolar lavage at day 3 and 5 were selected for sequencing. cDNA and multiplex
PCR reactions were prepared following the ARTIC SARS-CoV-2 sequencing protocol v2 (Tyson et al., 2020). The inoculum was
also sequenced. V3 primer scheme (https://github.com/artic-network/primer-schemes/tree/master/nCoV-2019/V3) was used to
perform the multiplex PCR for SARS-CoV-2. All samples were run for 35 cycles in the two multiplex PCRs. Pooled and cleaned
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PCR reactions were quantified using QubitTM fluorometer (Invitrogen). The Ligation Sequencing kit (SQK-LSK109; Oxford Nanopore
Technologies) was used to prepare the library following the manufacturer’s protocol (‘‘PCR tiling of COVID-19 virus,’’ release
F; Oxford Nanopore Technologies). 24 samples were multiplexed using Native Barcoding Expansion 1-12 and Native Barcoding
Expansion 13-24 kits (EXP-NBD104 and EXP-NBD114; Oxford Nanopore Technologies). Two libraries of 24 samples were prepared
independently and quantified by QubitTM fluorometer (Invitrogen). Quality control of two R9.4 flowcells (FLO-MIN106;
Oxford Nanopore Technologies) was performed to assess pores viability. Next, 45 and 32 ng of library were respectively loaded
as recommended by the manufacturer’s protocol. Sequencing was performed on a GridION (Oxford Nanopore Technologies) for
72 h with high-accuracy Guppy basecalling (v3.2.10). After sequencing, demultiplexing was performed using Guppy v4.0.14 with
the option–require_barcodes_both_ends to ensure high quality demultiplexing. Reads were then filtered by Nanoplot v1.28.1 based
on length and quality to select high quality reads. Then, reads were aligned on the SARS-CoV-2 reference genome NC_045512.2
using minimap2 v2.17. Primary alignments were filtered based on reads length alignment and reads identity. Finally, variant calling
was performed with Longshot v0.4.1. Identified variants were then analyzed using in-house scripts. Variants absent from the inoc-
ulum but present in one or more samples were selected for further analysis.
QUANTIFICATION AND STATISTICAL ANALYSIS
Details on the statistical analysis for the experiments can be found in the accompanying figure legends. Statistical significance be-
tween groups is indicated in the figures by stars: *, p < 0.05; **, p < 0.01; ***, p < 0.001; ****, p < 0.0001. In addition, statistical sig-
nificance between viral loads in the control and vaccinated groups are also indicated in the Results section by p values. Medians
are plotted for all experiments and comparisons between two groups were made using a Mann-Whitney U test (Excel 2016, Graph-
Pad Prism 8.0/7.0). For mouse experiments 8 animals were used up to week 6, when 2 animals were euthanized for preliminary
assessment of (N)Ab titers. Due to low sample volumes the eight mouse samples at week 1 were randomly paired and pooled
into 4 samples. The rabbit experiments were performed using 5 animals. In the macaque experiments, 6 animals were used in the
vaccinated group and 4 animals were used in the control group.
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Supplemental Figures
Figure S1. Site-specific glycan analysis of SARS-CoV-2 S I53-50NPs, related to Figure 1
(A) The table categorizes the glycan compositions into oligomannose-, hybrid-, and complex-type as well as the percentage of glycan species containing at least
one fucose or one sialic acid residue. The overall averages are shown in the right-hand table. (B) Site-specific distribution of N-linked glycans. The graphs
summarize quantitative mass spectrometric analysis of the glycan population present at individual N-linked glycosylation sites simplified into categories of
glycans. The oligomannose-type glycan series (M9 to M5; Man9GlcNAc2 to Man5GlcNAc2) is colored green, afucosylated and fucosylated hybrid-type glycans
(Hybrid & F Hybrid) dashed pink, and complex glycans grouped according to the number of antennae and presence of core fucosylation (HexNAc(3)(X) to
HexNAc(6+)(F)(X)) and are colored pink. Unoccupancy of an N-linked glycan site is represented in gray. The pie charts summarize the quantification of these
glycans. Glycan sites are colored according to oligomannose-type glycan content with the glycan sites labeled in green (80%100% oligomannose), orange
(30%79% oligomannose) and pink (0%29% oligomannose).
ll
OPEN ACCESSArticle
Figure S2. SARS-CoV-2 S-protein-specific CD27+ B cell responses in control and vaccinated macaques, related to Figure 4
(A) Representative gating strategy for the identification of SARS-CoV-2 S protein and RBD-specific CD27+ B cells for control (top) and vaccinated (bottom)
macaques. The live B cell population was selected and doubletswere excluded (not shown). (B) Frequency of SARS-CoV-2 S protein-specific cells amongCD27+
B cells in control and vaccinated macaques. (C) Frequency of SARS-CoV-2 RBD-specific cells among CD27+ B cells in control and vaccinated macaques. In (B)
and (C) bars indicate median. Groups were compared using the Mann-Whitney U test (*p < 0.05; **p < 0.01).
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Figure S3. SARS-CoV-2 S-protein-specific Tfh cell and CD4 T cell responses in control and vaccinated macaques, related to Figure 4
(A) Representative gating strategy for the identification of SARS-CoV-2 S protein-specific Tfh cells. PBMCswere stimulated overnight with SARS-CoV-2 S protein
and Tfh activation was assessed the next day by analyzing CD69 and CD154 expression. (B) Frequency of total Tfh cells in CD4+ T cell population following
stimulation with SARS-CoV-2 S protein. (C) Frequency of SARS-CoV-2 S-protein specific Tfh cells within the total Tfh cell population. Corresponding background
(i.e., frequency of activated Tfh cells in non-stimulated cells) has been subtracted from each data point. (D) Frequency of SARS-CoV-2 S protein-specific cells
among CD4- T cells (CD8+ T cells by inference) as determined by the AIM assay using 4-1BB + CD69 (left) and 4-1BB + CD154 (right) as activation markers.
Similar to (A), CD4- cells were stimulated overnight with SARS-CoV-2 S protein and activation was assessed using activation markers. Corresponding back-
ground (i.e., frequency of activated CD4- cells in non-stimulated cells) has been subtracted from each data point. In (B)-(D) bars indicate median.
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Figure S4. SARS-CoV-2 S-protein-specific Ig levels and Fc-receptor binding in vaccinated cynomolgus macaques in samples from diverse
anatomical sites, related to Figure 5
(A) Relative MFI of IgG (left), IgA (middle) and IgM (right) binding to SARS-CoV-2 S protein measured with a Luminex-based serology assay in serum samples. (B)
Relative MFI of IgG and IgA binding to SARS-CoV-2 S in nasopharyngeal swabs. (C) Relative MFI of IgG and IgA binding to SARS-CoV-2 S in saliva. (D) Relative
MFI of FcgRIIa (left), FcgRIIIa (middle) and C1q (right) binding to SARS-CoV-2 S protein-specific IgG in serum samples.
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Figure S5. Viral loads in control and vaccinated cynomolgus macaques after SARS-CoV-2 challenge, related to Figure 6
(A) RNA viral loads in tracheal swabs (top), nasopharyngeal swabs (middle) and rectal samples (bottom) of control (left) and SARS-CoV-2 S-I53-50NP vaccinated
macaques (right) after challenge. The gray line represents the median viral load. Vertical red dotted lines indicate the day of challenge. Horizontal dotted lines
indicate the limit of quantification. Symbols identify individual macaques. (B) Percentage of macaques in which the RNA viral loads is above the limit of quan-
tification over time in tracheal swabs (left) and nasopharyngeal swabs (right).
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Figure S6. Anamnestic immune response, lymphocyte counts, and emerged viral sequence variants in control and vaccinated cynomolgus
macaques after SARS-CoV-2 challenge, related to Figure 6
(A) SARS-CoV-2 pseudovirus neutralization titers. The gray line represents the median titers over-time. (B) SARS-CoV-2 authentic virus neutralization titers. The
gray line represents the median titers over-time. (C) Lymphocyte counts over time in the blood of control and SARS-CoV-2 S-I53-50NP vaccinated macaques
after challenge. Vertical red dotted lines indicate the day of challenge. In (A)-(C) Symbols identify individual macaques as indicated Figure S5A. (D) Sum of viral
variants found by viral sequencing, in nasopharyngeal swabs at 3 dpe and 5 dpe, and in BAL at 3 dpe, specified for the ORF in which it was found (top left) the type
of nucleotide change (top right) and the effect is has on the amino acid sequence (bottom; missense_variant = amino acid change, synonymous_variant = no
amino acid change, stop_gained = introduction of a stop codon). For a list of all identified variants see Table S3.
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